Ann Arbor, MI, United States of America

Shoujun Chen


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shoujun Chen: Innovator in Pharmaceutical Compounds

Introduction

Shoujun Chen is a notable inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific medical disorders. His work is characterized by a focus on innovative solutions for complex health issues.

Latest Patents

Shoujun Chen holds a patent for "Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease." This invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H-indazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound. He has 1 patent to his name.

Career Highlights

Shoujun Chen is currently associated with Lycera Corporation, where he continues to advance his research and development efforts. His work at Lycera Corporation emphasizes the importance of innovative pharmaceutical solutions that can address unmet medical needs.

Collaborations

Some of his notable coworkers include Thomas Daniel Aicher and Fernando Padilla. Their collaborative efforts contribute to the innovative environment at Lycera Corporation.

Conclusion

Shoujun Chen is a prominent figure in the pharmaceutical industry, recognized for his innovative contributions to medical science. His work on indazolyl thiadiazolamines showcases his commitment to developing effective treatments for various disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…